News
Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.
Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...
CEO says pharma executives discussed Trump's call to launch DTC initiatives under his Most Favored Nation policy to lower U.S ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...
Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results